Recombinant Erythropoietin Market, By Type (Epoetin Alfa, Darbepoetin Alfa), By Indication (Anemia Associated with Chronic Kidney Disease (CKD), Cancer Related Anemia, HIV-Associated Anemia, Others), By End-Use (Hospitals and Clinics, Dialysis Centers, Oncology Centers, Others), By Country, and By Region Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
REPORT HIGHLIGHT
Recombinant Erythropoietin Market size was valued at USD 6,851.28 Million in 2022, expanding at a CAGR of 2.1% from 2023 to 2030.
Recombinant erythropoietin (rEPO) is a genetically modified type of erythropoietin, a hormone generated normally in the kidneys that controls red blood cell synthesis. rEPO is created through biotechnology, often using mammalian cells. It possesses the same form and function as endogenous erythropoietin and is utilized for treating anemia-related illnesses including chronic kidney failure, cancer-related anemia, and anemia caused by certain medicinal therapies. rEPO increases oxygen-carrying capacity in the blood by promoting the synthesis of red blood cells, enhancing energy levels, and minimizing the requirement for blood transfusions in patients with anemia.
Recombinant Erythropoietin Market- Market Dynamics
- Rising frequency of chronic kidney disease (CKD) and the necessity for efficient anaemia therapy to propel market demand
The rising frequency of chronic kidney disease (CKD) and the necessity for efficient anemia therapy is driving demand for recombinant erythropoietin (rEPO). Anaemia is common in CKD patients due to decreased erythropoietin production. rEPO, also known as Epoetin Alfa, is used to increase red blood cell formation, easing anemia symptoms and minimizing the requirement for blood transfusions. As the worldwide prevalence of CKD climbs owing to reasons such as aging populations and lifestyle changes, the healthcare sector's need for rEPO as a vital therapeutic option for anemia treatment in CKD patients grows.
Recombinant Erythropoietin Market- Key Insights
- As per the analysis shared by our research analyst, the global Recombinant Erythropoietin market is estimated to grow annually at a CAGR of around 2.1% over the forecast period (2023-2030)
- The Recombinant Erythropoietin industry is projected to grow at a significant rate due to the rising frequency of chronic kidney disease (CKD) and the necessity for efficient anaemia therapy
- Based on Type segmentation, Epoetin Alfa was predicted to show maximum market share in the year 2022
- Based on Indication segmentation, Cancer Related Anemia was the leading type in 2022
- On the basis of region, Asia Pacific was the leading revenue generator in 2022
Recombinant Erythropoietin Market- Segmentation Analysis:
The Global Recombinant Erythropoietin Market is segmented on the basis of Type, Indication, End-Use, and Region.
The market is divided into two categories based on Type: Epoetin Alfa, Darbepoetin Alfa. Epoetin Alfa, a kind of recombinant erythropoietin (rEPO), is in high demand since it is frequently used to treat anemia caused by chronic kidney disease, cancer chemotherapy, and other medical diseases. Epoetin Alfa promotes red blood cell synthesis, which helps to reduce anemia symptoms and enhance patients' quality of life.
The market is divided into four categories based on Indication: Anemia Associated with Chronic Kidney Disease (CKD), Cancer Related Anemia, HIV-Associated Anemia, Others. The Cancer Related Anemia sector dominates the market and is likely to maintain its dominance during the forecast period. In the treatment of cancer-related anemia, recombinant erythropoietin (rEPO) is in great demand. Patients taking chemotherapy for cancer often have a reduction in red blood cell formation, resulting in anemia. rEPO, especially Epoetin Alfa, is used to increase red blood cell synthesis, lowering the need for blood transfusions and increasing the general well-being of cancer patients.
Recombinant Erythropoietin Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. Several reasons contribute to the high demand for recombinant erythropoietin (rEPO) in the Asia Pacific area. A considerable patient population in the area suffers from anemia-related illnesses such as chronic renal disease and cancer. Furthermore, the region's rapidly aging population and rising frequency of chronic illnesses boost demand for rEPO as a treatment option for anemia management. Furthermore, improving healthcare infrastructure as well as medical technology improvements led to the increased usage of rEPO in the Asia Pacific market. As a consequence, pharmaceutical firms are increasing their presence in the area to address the increasing demand for rEPO and other biologics.
Recombinant Erythropoietin Market- Competitive Landscape:
Because of its critical function in treating anemia-related disorders, recombinant erythropoietin (rEPO) faces severe competition. Several pharmaceutical firms are involved in the development and marketing of rEPO, creating a competitive environment. The market is dominated by key firms with well-established brands and substantial distribution networks. Companies strive for a competitive advantage by emphasizing product efficacy, safety, and cost-effectiveness. Furthermore, continuous R&D activities seek to enhance formulations and administration modalities, boosting patient comfort and compliance. The competitive dynamics are further influenced by strict regulatory compliance and patent protection.
Recent Developments:
- In February 2023, The Food and Drug Administration authorised Jesduvroq tablets (daprodustat) as the first oral medication for anaemia (low red blood cell count) caused by chronic renal disease in individuals who have been receiving on dialysis for at least a four-month period. Jesduvroq is not authorised for non-dialysis patients. Other FDA-approved therapies for this illness are administered through injection into the bloodstream or via the skin.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET KEY PLAYERS
- Amgen Inc.
- Johnson & Johnson
- LG Chem Ltd.
- Reddy's Laboratories Ltd.
- Celltrion Inc.
- Pfizer Inc.
- Roche Holding AG
- Novartis AG
- Biocon Limited
- Sandoz International GmbH
- Intas Pharmaceuticals Ltd.
- Teva Pharmaceutical Industries Ltd.
- 3SBio Inc.
- CJ CheilJedang Corporation
- BioSidus SA
GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET, BY TYPE
- Epoetin Alfa
- Darbepoetin Alfa
GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET, BY INDICATION
- Anemia Associated with Chronic Kidney Disease (CKD)
- Cancer Related Anemia
- HIV-Associated Anemia
- Others
GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET, BY END-USE
- Hospitals and Clinics
- Dialysis Centers
- Oncology Centers
- Others
GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Recombinant Erythropoietin Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Recombinant Erythropoietin Market Snippet by Type
2.1.2. Recombinant Erythropoietin Market Snippet by Indication
2.1.3. Recombinant Erythropoietin Market Snippet by End-Use
2.1.4. Recombinant Erythropoietin Market Snippet by Country
2.1.5. Recombinant Erythropoietin Market Snippet by Region
2.2. Competitive Insights
3. Recombinant Erythropoietin Key Market Trends
3.1. Recombinant Erythropoietin Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Recombinant Erythropoietin Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Recombinant Erythropoietin Market Opportunities
3.4. Recombinant Erythropoietin Market Future Trends
4. Recombinant Erythropoietin Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Recombinant Erythropoietin Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Recombinant Erythropoietin Market Landscape
6.1. Recombinant Erythropoietin Market Share Analysis, 2022
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Recombinant Erythropoietin Market – By Type
7.1. Overview
7.1.1. Segment Share Analysis, By Type, 2022 & 2030 (%)
7.1.2. Epoetin Alfa
7.1.3. Darbepoetin Alfa
8. Recombinant Erythropoietin Market – By Indication
8.1. Overview
8.1.1. Segment Share Analysis, By Indication, 2022 & 2030 (%)
8.1.2. Anemia Associated with Chronic Kidney Disease (CKD)
8.1.3. CancerRelated Anemia
8.1.4. HIV-Associated Anemia
8.1.5. Others
9. Recombinant Erythropoietin Market – By End-Use
9.1. Overview
9.1.1. Segment Share Analysis, By End-Use, 2022 & 2030 (%)
9.1.2. Hospitals and Clinics
9.1.3. Dialysis Centers
9.1.4. Oncology Centers
9.1.5. Others
10. Recombinant Erythropoietin Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
10.2. North America
10.2.1. Overview
10.2.2. Recombinant Erythropoietin Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.2.4. North America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.2.5. North America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.2.6. North America Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Recombinant Erythropoietin Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.6. Europe Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.3.8. Italy
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.8.3. Italy Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.8.4. Italy Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.8.5. Italy Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.3.9. United Kingdom
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.9.4. United Kingdom Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.9.5. United Kingdom Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.3.10. France
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.10.3. France Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.10.4. France Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.10.5. France Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.3.11. Russia
10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.11.2. Russia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.11.3. Russia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.11.4. Russia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.3.12. Netherlands
10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.12.2. Netherlands Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.12.3. Netherlands Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.12.4. Netherlands Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.3.13. Sweden
10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.13.2. Sweden Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.3.14. Poland
10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.14.2. Poland Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.14.3. Poland Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.14.4. Poland Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.3.15. Rest of Europe
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.15.4. Rest of the Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.3.15.5. Rest of the Europe Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Recombinant Erythropoietin Key Manufacturers in Asia Pacific
10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.4.4. Asia Pacific Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.5. Asia Pacific Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.6. Asia Pacific Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.4.7. India
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.7.3. India Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.7.4. India Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.7.5. India Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.4.8. China
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.8.3. China Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.8.4. China Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.8.5. China Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.4.12. Thailand
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.12.3. Thailand Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.12.4. Thailand Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.12.5. Thailand Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.4.13. Indonesia
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.13.3. Indonesia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.13.4. Indonesia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.13.5. Indonesia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.5. Latin America
10.5.1. Overview
10.5.2. Recombinant Erythropoietin Key Manufacturers in Latin America
10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.5.4. Latin America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.5.5. Latin America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.5.6. Latin America Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.6. Middle East and Africa
10.6.1. Overview
10.6.2. Recombinant Erythropoietin Key Manufacturers in Middle East and Africa
10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.6.6. Middle East and Africa Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.6.8. United Arab Emirates
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.6.8.4. United Arab Emirates Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.6.8.5. United Arab Emirates Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
11. Key Vendor Analysis- Recombinant Erythropoietin Industry
11.1. Competitive Dashboard
11.2. Company Profiles
11.2.1. Amgen Inc.
11.2.2. Johnson & Johnson
11.2.3. LG Chem Ltd.
11.2.4. Dr. Reddy's Laboratories Ltd.
11.2.5. Celltrion Inc.
11.2.6. Pfizer Inc.
11.2.7. Roche Holding AG
11.2.8. Novartis AG
11.2.9. Biocon Limited
11.2.10. Sandoz International GmbH
11.2.11. Intas Pharmaceuticals Ltd.
11.2.12. Teva Pharmaceutical Industries Ltd.
11.2.13. 3SBio Inc.
11.2.14. CJ CheilJedang Corporation
11.2.15. BioSidus SA
12. 360 Degree Analyst View
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
